Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Lung Neoplasms 8Carcinoma, Non-Small-Cell Lung 6Pancreatic Neoplasms 5Ovarian Neoplasms 5Colorectal Neoplasms 5Neoplasm Metastasis 4Fallopian Tube Neoplasms 4Multiple Myeloma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Primary Myelofibrosis 2Neoplasms 2Myelodysplastic Syndromes 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Glioblastoma 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1

Interventions

Cyclophosphamide 58Rituximab 54fludarabine 33fludarabine phosphate 32venetoclax 24Filgrastim 22Etoposide 18Bendamustine Hydrochloride 18Gemcitabine 17Peripheral Blood Stem Cell Transplantation 15Bortezomib 15Melphalan 14obinutuzumab 13Lenalidomide 12Dexamethasone 12Cytarabine 12Vincristine 11Vorinostat 10Tacrolimus 10Azacitidine 10pembrolizumab 9Prednisone 9Mycophenolic Acid 9Doxorubicin 9ibrutinib 8copanlisib 8Whole-Body Irradiation 8Radiotherapy 8Paclitaxel 8Interleukin-2 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, Non-Hodgkin × Disulfides × Clear all
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT02706405 2022-08-24

JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Fred Hutchinson Cancer Center

Phase 1 Terminated
30 enrolled 29 charts
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡